Department of Biochemistry Liaquat National Medical College, Karachi, Pakistan.
Department of Biochemistry Baqai Medical University, Karachi, Pakistan.
Pak J Pharm Sci. 2023 Jul;36(4):1085-1088.
Type 1 diabetes is a growing metabolic disorder, its ultimate therapy is the use of taking insulin regularly but, despite of that these patients cannot survive for longer durations due to poor glycaemic control, insulin resistance and development of complications. This clinical trial was designed to see if the addition of metformin can affect the dose of insulin and its complications and conducted for three months in Baqai Institute of Diabetology and Endocrinology. It included 80 patients of Type 1 Diabetes above 12 years of age between April 2019 to March 2020. Patients were divided into two groups. Group 1(n=30) was given Metformin with insulin and in Group 2 (n=50) patients were prescribed insulin only. Blood samples were collected at the beginning and end of trial to check Fasting and Random blood glucose and HbA1c levels. Paired sample t test and independent t test were applied, p value 0.05 was considered significant. A significant difference in HbA1c (p<0.001) and Random Blood Glucose (p=0.006) was noticed in group 1after three months. BMI increased in group 2, (p=0.024). The study concludes that Metformin might have a role in decreasing HbA1c and Random blood glucose levels in children above 12 years of age.
1 型糖尿病是一种日益严重的代谢紊乱疾病，其最终治疗方法是定期使用胰岛素，但尽管如此，由于血糖控制不佳、胰岛素抵抗和并发症的发展，这些患者无法长时间存活。这项临床试验旨在观察二甲双胍的添加是否会影响胰岛素的剂量及其并发症，并在 Baqai 糖尿病和内分泌学研究所进行了三个月。它纳入了 2019 年 4 月至 2020 年 3 月期间年龄在 12 岁以上的 80 名 1 型糖尿病患者。患者分为两组。第 1 组（n=30）给予胰岛素加二甲双胍，第 2 组（n=50）仅给予胰岛素。在试验开始和结束时采集血样，以检查空腹和随机血糖及 HbA1c 水平。应用配对样本 t 检验和独立样本 t 检验，p 值<0.05 认为有统计学意义。第 1 组在三个月后 HbA1c（p<0.001）和随机血糖（p=0.006）有显著差异。第 2 组 BMI 增加（p=0.024）。研究得出结论，二甲双胍可能在降低 12 岁以上儿童的 HbA1c 和随机血糖水平方面发挥作用。
